NanoSomix Aims to Launch Neural Exosome Biomarker Tech by Year-End

from GenomeWeb by Doug Macron

NEW YORK (GenomeWeb) – With the publication this week of data around its technology for the isolation and analysis of protein biomarkers in neural exosomes, startup NanoSomix is aiming to introduce a blood-based assay for Alzheimer’s disease-associated biomarkers before the end of the year.

The assay, dubbed NSX Direct, will measure two phosphorylated tau isoforms, total tau, and amyloid beta 1-42 — markers that are currently measured using either brain imaging or cerebrospinal fluid extraction, NanoSomix President and CEO John Osth told GenomeWeb. It will be first made available through an early-access program in the coming months, followed by a full commercial rollout thereafter.

NanoSomix is also planning to begin offering this year a service called NSX Enrich through which it will enrich plasma samples for neural exosomes that researchers can analyze for proteins, mRNA, and other components of interest, he said. (read more…)

Leave a Reply

Your email address will not be published. Required fields are marked *